‘It would simply
be too expensive…’
True,
anti-retroviral drugs are currently expensive, particularly taken in context
with other health priorities in the developing world. However, no one is expecting that poorer countries
will have to pay the premium prices that drug companies charge in the North
in order to recoup their research & development costs.
One reason why the drugs are so expensive here is that there
is such a relatively small and captive market.
However, once you multiply this up to global levels, simple competition
and market differentiation will drive prices right down. This is already happening, with generic drug
manufacturers, such as Cipla in India, now able to offer a year’s full treatment
with HAART for as little as $350, a mere fraction of the average cost in the
North. It is almost inevitable that
prices will fall to very near marginal costs of production in a year or so,
with brand name drugs and generic drugs ending up costing about the same.
The estimates often quoted by those who dismiss the possibility
of HAART are often wildly inaccurate, with costs of over $1000 per year sometimes
quoted. These figures are then multiplied
by >30 million erroneously assuming that one would try and treat nearly the
whole world’s HIV population. In reality, it would only make clinical and logistical sense to
aim to treat around 10% or 3 million, i.e. those with Grade 4 AIDS or about
one year left to live (see below).
Using these corrected figures, and accounting for the additional
costs of distribution, programme infrastructure, training, research and evaluation,
diagnostics and a salvage regime, it is now estimated that the total annual
costs of treating all those in the world that require it would be in the order
of $3.7 billion.
This may sound like a lot of money and it is, way beyond the
means of most countries in the south. However,
in global terms it is quite affordable, amounting to only 0.015% of the economic
output of the potential donor economies. Compare this with the amount the West
spends each year on agricultural subsidies, which is more than the entire GNP
of all the countries in Sub-Saharan Africa put together!
Yet, when Kofi Annan, General Secretary to the UN, asked the
world’s richer countries this year to donate between $7-10 bn to a Global Trust
Fund to tackle AIDS (including education, prevention and other measures), a
mere $700 million was committed, much of which was reallocated from previous
development budgets. Uganda even committed
more ($2m) to the new fund than Germany (zero)!